RSV vaccine still 43.3 percent effective 3 years after people take it, trial shows
GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% effective in preventing severe illness three years after patients 60 and older first received the shot.
RSV can be deadly, especially for older adults. What to know about symptoms and the new vaccine
In most cases, adequate hydration and over-the-counter pain relievers can help manage your symptoms during the week or two it takes to recover from RSV. But children under 5 and adults 60 and older are at high risk of severe infection resulting in hospitalization. The latter are also in danger of death.
GSK says RSV vaccine protects against disease over three seasons
Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.
What to know about the RSV vaccine ahead of virus season
Dr. Jaunita Mora said the respiratory syncytial virus is the leading cause of infant hospitalizations. Here are the people she said are most vulnerable to the disease.
Making an RSV Vaccine Was Hard. Getting People to Take It Is Even Harder
RSV hospitalizes thousands of people in the US every year. Three new vaccines could help stem the spread, but there are already huge inequities in access and uptake.
FierceBiotech27m
'Ongoing challenges' force Pfizer to scrap oral RSV med from ReViral buyout
In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...
Yes, you can get the COVID, flu, and RSV vaccines at once. Here are the pros and cons
Particularly if you tend not to have vaccine side effects, getting routine shots in one go may be a convenient option.
GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line up
U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...
FiercePharma5h
GSK touts 3-year data on RSV shot Arexvy after CDC's narrower usage recommendation
While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...
Low RSV and COVID vaccine usage is in line with investor expectations, but concerning: Jefferies
Low uptake in the RSV and COVID vaccine markets is not surprising, an analyst says, and could mean weak earnings for ...
GSK RSV shot 43% effective against severe disease in third year
GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...
What to know about COVID, flu and RSV vaccines for fall virus season
Infections caused by the latest variant have symptoms including fever, chills, fatigue, cough, congestion and headache.
GSK Announces Positive Data From AReSVi-006 Phase III Trial For RSV Vaccine Arexvy
GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating ...
COVID, RSV and flu cases expected to rise in Connecticut soon: 'Definitely upon us'
RSV rates can be expected to increase, and flu, as well as other common viruses. Human metapneumovirus tends to peak in ...
Free RSV shots now available for Ontario infants: ‘A very big deal for child health’
RSV is the most harmful respiratory illness for young infants, says Dr. Jeffrey Pernica, a professor in the Department of ...